Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$16.26 USD
-0.03 (-0.18%)
Updated Oct 4, 2024 03:56 PM ET
After-Market: $16.18 -0.08 (-0.49%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Pieris Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 59 | 118 | 70 | 104 |
Receivables | 6 | 6 | 3 | 2 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 8 | 7 | 4 | 4 |
Total Current Assets | 39 | 73 | 128 | 76 | 115 |
Net Property & Equipment | 0 | 17 | 19 | 22 | 20 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 3 | 3 | 3 |
Total Assets | 39 | 95 | 154 | 105 | 141 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 9 | 2 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 12 | 17 | 8 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 21 | 25 | 13 | 11 |
Total Current Liabilities | 12 | 37 | 51 | 22 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 19 | 38 | 36 | 47 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 68 | 103 | 74 | 90 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 342 | 319 | 307 | 243 | 227 |
Retained Earnings | -315 | -290 | -257 | -211 | -174 |
Other Equity | 0 | 0 | 1 | 0 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 28 | 51 | 31 | 51 |
Total Liabilities & Shareholder's Equity | 39 | 95 | 154 | 105 | 141 |
Total Common Equity | 27 | 28 | 51 | 31 | 51 |
Shares Outstanding | 1.20 | 0.90 | 0.90 | 0.70 | 0.60 |
Book Value Per Share | 22.30 | 31.03 | 56.40 | 44.33 | 85.58 |
Fiscal Year End for Pieris Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 20 | 19 | 26 | 45 | 55 |
Receivables | 5 | 7 | 6 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 3 | 6 | 11 | 11 |
Total Current Assets | 25 | 30 | 39 | 59 | 66 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 16 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 25 | 30 | 39 | 59 | 88 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 3 | 3 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 6 | 9 | 13 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 18 |
Total Current Liabilities | 6 | 8 | 12 | 29 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 8 | 12 | 29 | 47 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 343 | 342 | 342 | 341 | 340 |
Retained Earnings | -323 | -320 | -315 | -310 | -300 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 19 | 22 | 27 | 31 | 41 |
Total Liabilities & Shareholder's Equity | 25 | 30 | 39 | 59 | 88 |
Total Common Equity | 19 | 22 | 27 | 31 | 41 |
Shares Outstanding | 1.30 | 1.20 | 1.20 | 1.20 | 1.00 |
Book Value Per Share | 14.39 | 18.30 | 22.30 | 25.43 | 40.50 |